title: Bevacizumab treatment for subfoveal choroidal neovascularization from causes other than age-related macular degeneration.
abstract: OBJECTIVE
  To report the results of intravitreous bevacizumab (Avastin) treatment for choroidal neovascularization (CNV) from causes other than age-related macular degeneration (AMD).
  
  
  METHODS
  We performed a retrospective analysis of eyes that received intravitreous bevacizumab, 1.25 mg, for subfoveal non-AMD CNV at a referral-based retinal practice. Repeated treatment with intravitreous bevacizumab occurred if there were signs of persistent or recurrent exudation. The main outcome measure was visual acuity (VA).
  
  
  RESULTS
  The study included 39 eyes of 36 patients with subfoveal CNV secondary to multifocal choroiditis (n = 12), angioid streaks (n = 11), myopic degeneration (n = 10), idiopathic disease (n = 4), or other disease (n = 2). The median baseline VA was 20/60 (logMAR, 0.48). The mean follow-up was 58.8 weeks, and the mean number of injections per eye was 3.4. After 3-month follow-up, the median VA was 20/30 (logMAR, 0.18) (P = .004 vs baseline). At last follow-up, the median VA was 20/40 (logMAR, 0.30). This remained an improvement compared with baseline (P < .02) but was worse than 3-month follow-up (P < .03). There was no correlation between underlying diagnosis and VA change during follow-up.
  
  
  CONCLUSIONS
  Subfoveal CNV secondary to non-AMD causes treated with intravitreous bevacizumab responded favorably and similarly, despite varying underlying etiologies.
authors.affiliation: Vitreous, Retina, Macula Consultants of New York, 460 Park Ave, Fifth Floor, New York, NY 10022, USA.
authors.forename: Louis K
authors.initials: LK
authors.lastname: Chang
authors.forename: Richard F
authors.initials: RF
authors.lastname: Spaide
authors.forename: Claudia
authors.initials: C
authors.lastname: Brue
authors.forename: K Bailey
authors.initials: KB
authors.lastname: Freund
authors.forename: James M
authors.initials: JM
authors.lastname: Klancnik
authors.forename: Jason S
authors.initials: JS
authors.lastname: Slakter
mesh_terms: D000328:Adult; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000793:Angioid Streaks / Q000150:complications*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000209:etiology; D002833:Choroiditis / Q000150:complications*; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D005584:Fovea Centralis; D006801:Humans; D007267:Injections; D008268:Macular Degeneration / Q000150:complications; D008297:Male; D008875:Middle Aged; D047728:Myopia, Degenerative / Q000150:complications*; D010778:Photochemotherapy; D012189:Retrospective Studies; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D014222:Triamcinolone Acetonide / Q000627:therapeutic use; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity; D014822:Vitreous Body
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D014222:Triamcinolone Acetonide